Targeting the NLRP3 inflammasome in inflammatory diseases von Mangan, Matthew S. J., Olhava, Edward J., Roush, William R., Seidel, H. Martin, Glick, Gary D., Latz, Eicke

Volltext

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia von Daigle, Scott R., Olhava, Edward J., Therkelsen, Carly A., Basavapathruni, Aravind, Jin, Lei, Boriack-Sjodin, P. Ann, Allain, Christina J., Klaus, Christine R., Raimondi, Alejandra, Scott, Margaret Porter, Waters, Nigel J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A., Richon, Victoria M., Pollock, Roy M.

Volltext

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells von Knutson, Sarah K, Wigle, Tim J, Warholic, Natalie M, Sneeringer, Christopher J, Allain, Christina J, Klaus, Christine R, Sacks, Joelle D, Raimondi, Alejandra, Majer, Christina R, Song, Jeffrey, Scott, Margaret Porter, Jin, Lei, Smith, Jesse J, Olhava, Edward J, Chesworth, Richard, Moyer, Mikel P, Richon, Victoria M, Copeland, Robert A, Keilhack, Heike, Pollock, Roy M, Kuntz, Kevin W

Volltext

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor von Daigle, Scott R., Olhava, Edward J., Therkelsen, Carly A., Majer, Christina R., Sneeringer, Christopher J., Song, Jeffrey, Johnston, L. Danielle, Scott, Margaret Porter, Smith, Jesse J., Xiao, Yonghong, Jin, Lei, Kuntz, Kevin W., Chesworth, Richard, Moyer, Mikel P., Bernt, Kathrin M., Tseng, Jen-Chieh, Kung, Andrew L., Armstrong, Scott A., Copeland, Robert A., Richon, Victoria M., Pollock, Roy M.

Volltext

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l von Deshpande, Aniruddha J., Chen, Liying, Fazio, Maurizio, Sinha, Amit U., Bernt, Kathrin M., Banka, Deepti, Dias, Stuart, Chang, Jenny, Olhava, Edward J., Daigle, Scott R., Richon, Victoria M., Pollock, Roy M., Armstrong, Scott A.

Volltext

Enantioselective Synthesis of Dihydropyrans. Catalysis of Hetero Diels−Alder Reactions by Bis(oxazoline) Copper(II) Complexes von Evans, David A, Johnson, Jeffrey S, Olhava, Edward J

Volltext

Total Synthesis of (+)-Azaspiracid-1. An Exhibition of the Intricacies of Complex Molecule Synthesis von Evans, David A, Kværnø, Lisbet, Dunn, Travis B, Beauchemin, André, Raymer, Brian, Mulder, Jason A, Olhava, Edward J, Juhl, Martin, Kagechika, Katsuji, Favor, David A

Volltext

Total Synthesis of (+)-Azaspiracid-1. Part II: Synthesis of the EFGHI Sulfone and Completion of the Synthesis von Evans, David A., Dunn, Travis B., Kværnø, Lisbet, Beauchemin, André, Raymer, Brian, Olhava, Edward J., Mulder, Jason A., Juhl, Martin, Kagechika, Katsuji, Favor, David A.

Volltext

Targeting epigenetic enzymes for drug discovery von Copeland, Robert A, Olhava, Edward J, Scott, Margaret Porter

Volltext

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition von Kühn, Michael W M, Hadler, Michael J, Daigle, Scott R, Koche, Richard P, Krivtsov, Andrei V, Olhava, Edward J, Caligiuri, Michael A, Huang, Gang, Bradner, James E, Pollock, Roy M, Armstrong, Scott A

Volltext

DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells von Klaus, Christine R, Iwanowicz, Dorothy, Johnston, Danielle, Campbell, Carly A, Smith, Jesse J, Moyer, Mikel P, Copeland, Robert A, Olhava, Edward J, Scott, Margaret Porter, Pollock, Roy M, Daigle, Scott R, Raimondi, Alejandra

Volltext

Total Synthesis of (+)-Azaspiracid-1. Part I: Synthesis of the Fully Elaborated ABCD Aldehyde von Evans, David A., Kværnø, Lisbet, Mulder, Jason A., Raymer, Brian, Dunn, Travis B., Beauchemin, André, Olhava, Edward J., Juhl, Martin, Kagechika, Katsuji

Volltext

Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL -Rearranged Leukemia von Campbell, Carly T, Haladyna, Jessica N, Drubin, David A, Thomson, Ty M, Maria, Michael J, Yamauchi, Taylor, Waters, Nigel J, Olhava, Edward J, Pollock, Roy M, Smith, Jesse J, Copeland, Robert A, Blakemore, Stephen J, Bernt, Kathrin M, Daigle, Scott R

Volltext

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit von Blackburn, Christopher, Gigstad, Kenneth M., Hales, Paul, Garcia, Khristofer, Jones, Matthew, Bruzzese, Frank J., Barrett, Cynthia, Liu, Jane X., Soucy, Teresa A., Sappal, Darshan S., Bump, Nancy, Olhava, Edward J., Fleming, Paul, Dick, Lawrence R., Tsu, Christopher, Sintchak, Michael D., Blank, Jonathan L.

Volltext

Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L von Basavapathruni, Aravind, Jin, Lei, Daigle, Scott R., Majer, Christina R. A., Therkelsen, Carly A., Wigle, Tim J., Kuntz, Kevin W., Chesworth, Richard, Pollock, Roy M., Scott, Margaret P., Moyer, Mikel P., Richon, Victoria M., Copeland, Robert A., Olhava, Edward J.

Volltext

Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic ta... von Waters, Nigel J., Daigle, Scott R., Rehlaender, Bruce N., Basavapathruni, Aravind, Campbell, Carly T., Jensen, Tyler B., Truitt, Brett F., Olhava, Edward J., Pollock, Roy M., Stickland, Kim A., Dovletoglou, Angelos

Volltext

Targeting the NLRP3 inflammasome in inflammatory diseases von Mangan, Matthew S J, Olhava, Edward J, Roush, William R, Seidel, H Martin, Glick, Gary D, Latz, Eicke

Volltext

Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases von Mangan, Matthew S. J., Olhava, Edward J., Roush, William R., Seidel, H. Martin, Glick, Gary D., Latz, Eicke

Volltext

Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human von Waters, Nigel J., Smith, Sherri A., Olhava, Edward J., Duncan, Kenneth W., Burton, Richard D., O’Neill, James, Rodrigue, Marie-Eve, Pollock, Roy M., Moyer, Mikel P., Chesworth, Richard

Volltext

Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor von Basavapathruni, Aravind, Olhava, Edward J., Daigle, Scott R., Therkelsen, Carly A., Jin, Lei, Boriack-Sjodin, P. Ann, Allain, Christina J., Klaus, Christine R., Raimondi, Alejandra, Scott, Margaret Porter, Dovletoglou, Angelos, Richon, Victoria M., Pollock, Roy M., Copeland, Robert A., Moyer, Mikel P., Chesworth, Richard, Pearson, Paul G., Waters, Nigel J.

Volltext